# US 12,180,274 B2 · Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,274 B2
- Document ID: US12180274B2
- Status: Granted
- Kind: B2
- Application number: 18/324,915
- Filed: 2023-05-26
- Published: 2024-11-28
- Granted: 2024-12-31
- Earliest claimed: 2023-05-26
- Assignees: InflaRx GmbH
- Applicants: InflaRx GmbH
- Inventors: Niels Christoph Riedemann; Renfeng Guo
- Web page: https://patentgrep.com/patent/US12180274B2

## CPC

- C07K 16/248: {IL-6}
- A61P 11/00: Drugs for disorders of the respiratory system
- C07K 16/18: against material from animals or humans
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to an inhibitor of C5a activity and an inhibitor of IL-6 activity for use in the treatment of infectious pneumonia and infectious acute respiratory distress syndrome (ARDS). In further aspects administration regimes and kit of parts are referred to.

## Claims

### Claim 1

A method of treating infectious pneumonia and/or infectious acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 infection, the method comprising:
administering to a patient in need thereof an inhibitor of C5a activity
(i) in combination with an inhibitor of IL-6 activity; and/or
(ii) wherein the patient is or has been treated with an inhibitor of IL-6 activity; and
wherein the inhibitor of C5a activity is vilobelimab and the inhibitor of IL-6 activity is tocilizumab.

### Claim 2 (depends on 1)

The method of claim 1, wherein said administering comprises a regime comprising an induction phase followed by a maintenance phase, wherein the inhibitor of C5a activity is administered in the induction phase and the maintenance phase and the inhibitor of IL-6 activity is administered:
(I) within 0-30 days prior to the induction phase,
(II) during the induction phase, and/or
(III) during the maintenance phase.

### Claim 3 (depends on 2)

The method of claim 2, wherein:
(i) the induction phase comprises or consists essentially of a period of 1 to 10 days, wherein 1-8 doses, each comprising 200-1600 mg of said inhibitor of C5a activity, are administered; and
(ii) the maintenance phase comprises or consists essentially of a period of at least 2 weeks, wherein a dose, comprising 200-1600 mg of said inhibitor of C5a activity, is administered every 1-4 weeks.

### Claim 4 (depends on 2)

The method of claim 2, wherein:
(i) 1 or 2 doses of the inhibitor of IL-6 activity is administered within 0 to 14 days prior and/or after the start of the induction phase; and/or
(ii) the inhibitor of IL-6 activity is administered at a weight dependent dose of 8 mg/kg for patients at or above 30 kg weight or 12 mg/kg for patients of less than 30 kg weight.